Farcast Biosciences competitors

Steven James has over 30 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Currently, Mr. James is Chief Executive Officer and director of Pionyr Immunotherapeutics. Previously, he was president and CEO of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Mr. James was president and CEO of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. He serves as a trustee of Middlebridge School in Rhode Island. Mr. James is currently chairman of Antiva Biosciences and Soteria Therapeutics and a director of Allakos Inc and Ventus Therapeutics. He was formerly a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics).

Jeff Knapp has over 30 years of experience in the pharmaceutical industry, including 20 in executive management. He has developed and executed strategies supporting clinical development, regulatory approval, and commercial launch of multiple products across a diverse array of therapeutic areas. Prior to joining DNAtrix, Jeff served as Chief Operating Officer at Aimmune Therapeutics where he was responsible for preparing the company’s first asset, AR101, for approval and commercial launch in the US & EU as a treatment for children and adolescents with peanut allergies. Before joining Aimmune, Jeff served as Chief Operating Officer at Adamas Pharmaceuticals. While working with Adamas, Jeff established the preliminary commercial and manufacturing infrastructure as the company moved from a privately held Phase 2 company to a publicly-traded Phase 3 / pre-commercial company and supported the company’s successful Initial Public Offering in April 2014. Jeff also served as Chief Commercial Officer at Affymax, where he developed the strategy and led the build out of the commercial organization leading to the successful 2012 launch of the company’s lead compound, OMONTYS® (peginesatide), for the treatment of anemia in patients with end-stage renal disease. Earlier in his career, Jeff held several senior positions in Sales and Marketing, including Senior Vice President and Vice President, at companies such as Abgenix (acquired by Amgen in April 2006), Pharmion Corporation, EMD Pharmaceuticals (a division of Merck KGaA), and the Oncology Division of Eli Lilly and Schering-Plough Corporation. Jeff received a BA in Biology with a Minor in Business Administration from Wittenberg University.

Robert Ross is a Board Member at Obsidian Therapeutics, Board Member at SURFACE ONCOLOGY INC., and Chief Executive Officer at SURFACE ONCOLOGY INC. and is based in Brookline, Massachusetts. He has worked as Chief Medical Officer at SURFACE ONCOLOGY INC.. Robert studied at Columbia University in the City of New York between 1995 and 1999, Teachers College Columbia University, and Harvard University between 2005 and 2007.